PP
SAGE

Paloma Partners’s Sage Therapeutics SAGE Stock Holding History

Paloma Partners’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-30,467
Closed -$1.86M – 2147
2020
Q3 		$1.86M Sell
30,467
-15,805
-34% -$801K 0.05% 416
2020
Q2 		$1.92M Buy
+46,272
New +$1.68M 0.03% 643
2019
Q4 		– Sell
-2,284
Closed -$320K – 2448
2019
Q3 		$320K Buy
+2,284
New +$382K 0.01% 1482
2018
Q3 		– Sell
-104,899
Closed -$16.4M – 1894
2018
Q2 		$16.4M Buy
+104,899
New +$16.5M 0.3% 42
2018
Q1 		– Sell
-2,210
Closed -$363K – 2225
2017
Q4 		$363K Sell
2,210
-2,080
-48% -$202K ﹤0.01% 1461
2017
Q3 		$268K Buy
+4,290
New +$337K ﹤0.01% 1850

Other funds holding SAGE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Paloma Partners's SAGE Position: Q4 2020 in Review

Paloma Partners sold out of Sage Therapeutics (SAGE) in Q4 2020, closing a stake of 30,467 shares — an estimated $1.86M sold.

Paloma Partners first reported a position in SAGE in Q3 2017 and held it in 6 quarters. The position peaked at $16.4M in Q2 2018. 248 funds tracked by Wall St. Rank hold SAGE as of Q4 2020.

  • Paloma Partners reported no remaining Sage Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Paloma Partners sold 30,467 Sage Therapeutics shares in Q4 2020, an estimated $1.86M.
  • Paloma Partners first reported a position in Sage Therapeutics in Q3 2017 and held it in 6 quarters.
  • Paloma Partners's Sage Therapeutics position peaked at $16.4M in Q2 2018.
  • 248 funds tracked by Wall St. Rank held Sage Therapeutics as of Q4 2020.

Based on Paloma Partners's 13F filing for Q4 2020, filed 16 Feb 2021.